Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Small Molecule Libraries | 11 | 2024 | 118 | 3.130 |
Why?
|
| Drug Discovery | 7 | 2024 | 170 | 1.740 |
Why?
|
| Drug Design | 4 | 2021 | 146 | 1.720 |
Why?
|
| DNA | 8 | 2024 | 1588 | 1.510 |
Why?
|
| Piperazines | 2 | 2022 | 230 | 1.380 |
Why?
|
| Protease Inhibitors | 2 | 2022 | 93 | 0.920 |
Why?
|
| Molecular Structure | 9 | 2024 | 284 | 0.910 |
Why?
|
| Pyridines | 2 | 2021 | 224 | 0.880 |
Why?
|
| Diamines | 1 | 2022 | 8 | 0.810 |
Why?
|
| Alkenes | 2 | 2013 | 5 | 0.800 |
Why?
|
| Stereoisomerism | 7 | 2024 | 103 | 0.760 |
Why?
|
| Tudor Domain | 1 | 2021 | 6 | 0.740 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 6 | 0.730 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 49 | 0.730 |
Why?
|
| Fluorenes | 1 | 2020 | 7 | 0.720 |
Why?
|
| Molecular Probes | 1 | 2020 | 30 | 0.710 |
Why?
|
| Peptides | 2 | 2020 | 792 | 0.690 |
Why?
|
| Molecular Biology | 1 | 2020 | 77 | 0.690 |
Why?
|
| Staining and Labeling | 1 | 2020 | 183 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 186 | 0.640 |
Why?
|
| Contraceptive Agents, Male | 3 | 2024 | 23 | 0.600 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 352 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 524 | 0.560 |
Why?
|
| Macrocyclic Compounds | 2 | 2011 | 9 | 0.470 |
Why?
|
| Structure-Activity Relationship | 4 | 2024 | 567 | 0.430 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2024 | 59 | 0.430 |
Why?
|
| Siloxanes | 1 | 2013 | 2 | 0.430 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2013 | 5 | 0.430 |
Why?
|
| Triazoles | 3 | 2021 | 138 | 0.410 |
Why?
|
| Molecular Conformation | 3 | 2021 | 100 | 0.390 |
Why?
|
| Luciferases | 3 | 2022 | 137 | 0.390 |
Why?
|
| Aza Compounds | 1 | 2011 | 15 | 0.380 |
Why?
|
| Silanes | 1 | 2011 | 1 | 0.380 |
Why?
|
| Ketones | 1 | 2011 | 24 | 0.380 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2011 | 5 | 0.380 |
Why?
|
| Nuclear Proteins | 3 | 2022 | 1268 | 0.360 |
Why?
|
| Azepines | 2 | 2021 | 61 | 0.350 |
Why?
|
| Biological Assay | 2 | 2022 | 100 | 0.350 |
Why?
|
| Ligands | 5 | 2022 | 533 | 0.330 |
Why?
|
| Catalysis | 5 | 2020 | 125 | 0.320 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2021 | 14 | 0.310 |
Why?
|
| Signal Transduction | 6 | 2024 | 4493 | 0.310 |
Why?
|
| Transcription Factors | 3 | 2022 | 2585 | 0.270 |
Why?
|
| Esters | 2 | 2024 | 29 | 0.260 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2005 | 9 | 0.260 |
Why?
|
| Databases, Factual | 1 | 2011 | 1172 | 0.260 |
Why?
|
| Lithium | 1 | 2005 | 66 | 0.250 |
Why?
|
| Pyridones | 1 | 2005 | 112 | 0.240 |
Why?
|
| Neoplasms | 1 | 2019 | 2755 | 0.240 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 33 | 0.240 |
Why?
|
| Microsomes, Liver | 2 | 2023 | 85 | 0.230 |
Why?
|
| Morpholines | 1 | 2024 | 56 | 0.220 |
Why?
|
| Protein Binding | 4 | 2022 | 1741 | 0.220 |
Why?
|
| Contraception | 1 | 2024 | 58 | 0.220 |
Why?
|
| Enzyme Activation | 2 | 2022 | 617 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 288 | 0.220 |
Why?
|
| Neurogenesis | 2 | 2022 | 196 | 0.210 |
Why?
|
| Crystallography, X-Ray | 2 | 2021 | 357 | 0.210 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 10 | 0.210 |
Why?
|
| Cosmic Radiation | 1 | 2022 | 11 | 0.200 |
Why?
|
| Acetic Acid | 1 | 2022 | 18 | 0.200 |
Why?
|
| Gold | 1 | 2022 | 48 | 0.200 |
Why?
|
| Oleic Acid | 1 | 2022 | 15 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 106 | 0.200 |
Why?
|
| Radiation Protection | 1 | 2022 | 54 | 0.200 |
Why?
|
| Astronauts | 1 | 2022 | 50 | 0.200 |
Why?
|
| Radiation Exposure | 1 | 2022 | 43 | 0.190 |
Why?
|
| Binding Sites | 2 | 2021 | 1292 | 0.180 |
Why?
|
| Radiation Injuries | 1 | 2022 | 141 | 0.180 |
Why?
|
| Solutions | 1 | 2020 | 65 | 0.180 |
Why?
|
| Space Flight | 1 | 2022 | 115 | 0.180 |
Why?
|
| Spliceosomes | 1 | 2021 | 53 | 0.180 |
Why?
|
| Genetic Engineering | 1 | 2021 | 161 | 0.180 |
Why?
|
| Oxygen | 1 | 2024 | 550 | 0.180 |
Why?
|
| Histone Code | 1 | 2021 | 54 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2020 | 117 | 0.170 |
Why?
|
| Cyclization | 3 | 2020 | 15 | 0.170 |
Why?
|
| Animals | 13 | 2024 | 33792 | 0.170 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 57 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 303 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 180 | 0.170 |
Why?
|
| Models, Molecular | 2 | 2021 | 1070 | 0.170 |
Why?
|
| Hippocampus | 2 | 2022 | 819 | 0.170 |
Why?
|
| Humans | 23 | 2024 | 123103 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2020 | 179 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 383 | 0.160 |
Why?
|
| Drosophila melanogaster | 1 | 2023 | 744 | 0.150 |
Why?
|
| Virus Replication | 1 | 2021 | 603 | 0.150 |
Why?
|
| Escherichia coli | 2 | 2021 | 983 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 228 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1681 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 399 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 570 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 175 | 0.140 |
Why?
|
| Histones | 1 | 2021 | 527 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2021 | 747 | 0.140 |
Why?
|
| Mice | 10 | 2024 | 17537 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2022 | 743 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 643 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2019 | 328 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2021 | 3040 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 4 | 2022 | 1339 | 0.120 |
Why?
|
| Metabolomics | 3 | 2023 | 408 | 0.120 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 8 | 0.110 |
Why?
|
| Substrate Specificity | 2 | 2011 | 283 | 0.110 |
Why?
|
| Chemistry, Organic | 1 | 2013 | 4 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1660 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2023 | 191 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3545 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 151 | 0.100 |
Why?
|
| Biological Products | 2 | 2010 | 113 | 0.100 |
Why?
|
| Palladium | 1 | 2011 | 12 | 0.100 |
Why?
|
| Carbamates | 1 | 2011 | 58 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 227 | 0.090 |
Why?
|
| Aldehydes | 1 | 2010 | 28 | 0.090 |
Why?
|
| Gene Library | 2 | 2023 | 220 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 544 | 0.090 |
Why?
|
| Testis | 2 | 2024 | 405 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 74 | 0.090 |
Why?
|
| Amino Acids | 2 | 2024 | 657 | 0.090 |
Why?
|
| Systems Biology | 1 | 2010 | 56 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 114 | 0.090 |
Why?
|
| Ruthenium | 1 | 2009 | 4 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 809 | 0.080 |
Why?
|
| Alkynes | 1 | 2009 | 26 | 0.080 |
Why?
|
| Disease | 1 | 2010 | 129 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2020 | 384 | 0.080 |
Why?
|
| Plasmids | 2 | 2020 | 511 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 2 | 2021 | 96 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 3291 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1386 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2021 | 940 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 1872 | 0.070 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 30 | 0.060 |
Why?
|
| Proteins | 1 | 2010 | 1037 | 0.060 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 11 | 0.060 |
Why?
|
| Receptors, Eph Family | 1 | 2024 | 21 | 0.060 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 26 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2024 | 44 | 0.060 |
Why?
|
| Carbon | 1 | 2024 | 91 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2023 | 10 | 0.060 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 16 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 444 | 0.050 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2022 | 11 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 32 | 0.050 |
Why?
|
| Moon | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2022 | 48 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 399 | 0.050 |
Why?
|
| Semen | 1 | 2022 | 75 | 0.050 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2022 | 23 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 128 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 100 | 0.050 |
Why?
|
| Glutathione | 1 | 2023 | 193 | 0.050 |
Why?
|
| Serotonin | 1 | 2022 | 232 | 0.050 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2021 | 15 | 0.050 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 16 | 0.050 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2021 | 16 | 0.050 |
Why?
|
| Protein Domains | 1 | 2022 | 233 | 0.050 |
Why?
|
| Endometriosis | 1 | 2024 | 185 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 63 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 831 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 137 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 112 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 43 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2021 | 228 | 0.040 |
Why?
|
| Buffers | 1 | 2020 | 31 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 89 | 0.040 |
Why?
|
| Introns | 1 | 2021 | 301 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 288 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 73 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 224 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 892 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 352 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 1068 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 664 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 738 | 0.040 |
Why?
|
| Male | 4 | 2024 | 60129 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 1565 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 2307 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 3722 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1782 | 0.030 |
Why?
|
| Female | 3 | 2024 | 65514 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 482 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 151 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1584 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 182 | 0.020 |
Why?
|